0.10Open0.10Pre Close0 Volume35 Open Interest22.50Strike Price0.00Turnover227.17%IV160.67%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0612Delta0.0265Gamma86.70Leverage Ratio-0.0137Theta0.0002Rho5.30Eff Leverage0.0024Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet